ORUM (KQ:475830) — Market Cap & Net Worth
Market Cap & Net Worth: ORUM (475830)
ORUM (KQ:475830) has a market capitalization of $729.52 Million (₩1.08 Trillion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #10375 globally and #277 in its home market, demonstrating a -4.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ORUM's stock price ₩50700.00 by its total outstanding shares 21232368 (21.23 Million). Also see how large is ORUM's balance sheet for a full breakdown of the balance sheet.
ORUM Market Cap History: 2025 to 2026
ORUM's market capitalization history from 2025 to 2026. Data shows growth from $1.73 Billion to $729.52 Million (0.00% CAGR). Also see ORUM cash flow conversion for how efficiently the company converts equity into cash flow.
ORUM Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ORUM's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 475830 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
73.27x
ORUM's market cap is 73.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $1.73 Billion | $23.56 Million | -$41.97 Billion | 73.27x | N/A |
Competitor Companies of 475830 by Market Capitalization
Companies near ORUM in the global market cap rankings as of September 18, 2026. Review 475830 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ORUM by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
ORUM Historical Marketcap From 2025 to 2026
Between 2025 and today, ORUM's market cap moved from $1.73 Billion to $ 729.52 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩729.52 Million | -57.75% |
| 2025 | ₩1.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of ORUM was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $729.52 Million USD |
| MoneyControl | $729.52 Million USD |
| MarketWatch | $729.52 Million USD |
| marketcap.company | $729.52 Million USD |
| Reuters | $729.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid … Read more